PIK3CA and breast cancer: When extended to patients with BC from the MSKCC non-ICI cohort, the TP53/PIK3CA/ATM mutation classifier did not show significant differences between the three groups (median OS, low-risk group: not reached; moderate-risk group: 30.5 months; high-risk group: not reached; P= 0.27) (Supplementary Figure 6A).